← Leaderboards
Alison T Stopeck
University Of Arizona
$4,717,705
Attributed
$7,405,306
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $703K · FY2006–24$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,405,306 · 4
By mechanism
R01$7,102,306 · 3
R21$303,000 · 1
Top collaborators
- Patricia Ann Thompson-Carino11 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Andrew Paul Capaldi$6,916,808
- Garth Powis$46,106,518
- Pascale G Charest$1,607,562
- Ghassan Mouneimne$1,881,114
- Jacquelyn Gervay-Hague$1,867,081
Others in their field
Top investigators on “Magnetic Resonance Imaging”
- Michael W Weiner · Northern California Institute Res &Educ$151,227,246
- Paul S. Aisen · Cognition Therapeutics, Inc.$114,102,468
- Reisa A. Sperling · Banner Health$112,709,449
- Randall J Bateman · Washington University$108,056,165
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
Magnetic Resonance ImagingTumorMorbidity - Disease RateTissuesMalignant Breast NeoplasmImageDiffusionBiological MarkersPre-ClinicalPre-Clinical ModelMalignant NeoplasmsMediatingAromatase InhibitorsDrug UsagePharmaceutical PreparationsBiopsyBreastCancer RecurrenceCessation Of LifeBreast Cancer ModelMammary Gland ParenchymaNon-Steroidal Anti-Inflammatory AgentsBreast DensityPain
Grant awards (18)
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$597,059
R01 · FY2024 · CA
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$702,967
R01 · FY2023 · CA
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$567,232
R01 · FY2022 · CA
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$581,171
R01 · FY2020 · CA
Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk$546,274
R01 · FY2019 · CA
Nsaid Effects on Clinical and Imaging Breast Biomarkers$449,101
R01 · FY2016 · CA · contact PI
Nsaid Effects on Clinical and Imaging Breast Biomarkers$321,311
R01 · FY2015 · CA · contact PI
Nsaid Effects on Clinical and Imaging Breast Biomarkers$486,805
R01 · FY2014 · CA · contact PI
Nsaid Effects on Clinical and Imaging Breast Biomarkers$138,298
R01 · FY2014 · CA · contact PI
Nsaid Effects on Clinical and Imaging Breast Biomarkers$584,187
R01 · FY2013 · CA · contact PI
Nsaid Effects on Clinical and Imaging Breast Biomarkers$400,797
R01 · FY2012 · CA · contact PI
DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES$353,041
R01 · FY2010 · CA · contact PI
DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES$348,975
R01 · FY2009 · CA · contact PI
DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES$341,662
R01 · FY2008 · CA · contact PI
DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES$341,191
R01 · FY2007 · CA · contact PI
DIFFUSION MRI AS BIOMARKER FOR THERAPY RESPONSE IN BREAST CANCER METASTASES$342,235
R01 · FY2006 · CA · contact PI
DIFFUSION MRI AND CHEMOTHERAPEUTIC RESPONSE$151,500
R21 · FY2001 · CA
DIFFUSION MRI AND CHEMOTHERAPEUTIC RESPONSE$151,500
R21 · FY2000 · CA